302 related articles for article (PubMed ID: 17207607)
1. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
[TBL] [Abstract][Full Text] [Related]
2. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
3. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
4. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
[TBL] [Abstract][Full Text] [Related]
5. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.
Bowker KE; Noel AR; MacGowan AP
J Antimicrob Chemother; 2006 Oct; 58(4):802-5. PubMed ID: 16891629
[TBL] [Abstract][Full Text] [Related]
8. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
Bowker KE; Noel AR; MacGowan AP
J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
[TBL] [Abstract][Full Text] [Related]
9. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
Huang V; Rybak MJ
J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
[TBL] [Abstract][Full Text] [Related]
12. Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.
Rose WE; Rybak MJ; Tsuji BT; Kaatz GW; Sakoulas G
J Antimicrob Chemother; 2007 Jun; 59(6):1190-3. PubMed ID: 17434881
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
14. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models.
Smirnova MV; Vostrov SN; Strukova EV; Dovzhenko SA; Kobrin MB; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2009 Oct; 64(4):815-20. PubMed ID: 19671586
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.
Begic D; von Eiff C; Tsuji BT
J Antimicrob Chemother; 2009 May; 63(5):977-81. PubMed ID: 19304733
[TBL] [Abstract][Full Text] [Related]
17. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
Xiao XM; Xiao YH
Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
[TBL] [Abstract][Full Text] [Related]
20. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Firsov AA; Zinner SH; Vostrov SN; Portnoy YA; Lubenko IY
J Antimicrob Chemother; 2002 Oct; 50(4):533-9. PubMed ID: 12356798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]